JP2009517340A5 - - Google Patents

Info

Publication number

JP2009517340A5

JP2009517340A5 JP2008539068A JP2008539068A JP2009517340A5 JP 2009517340 A5 JP2009517340 A5 JP 2009517340A5 JP 2008539068 A JP2008539068 A JP 2008539068A JP 2008539068 A JP2008539068 A JP 2008539068A JP 2009517340 A5 JP2009517340 A5 JP 2009517340A5

Authority

JP

Japan

Prior art keywords

antagonist

composition

soluble

disease

polypeptide

Prior art date

2006-11-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000005557 antagonist Substances 0.000 claims 31
• 108091033319 polynucleotide Proteins 0.000 claims 14
• 239000002157 polynucleotide Substances 0.000 claims 14
• 102000040430 polynucleotide Human genes 0.000 claims 14
• 229920001184 polypeptide Polymers 0.000 claims 14
• 102000004196 processed proteins & peptides Human genes 0.000 claims 14
• 108090000765 processed proteins & peptides Proteins 0.000 claims 14
• 210000005064 dopaminergic neuron Anatomy 0.000 claims 13
• 239000012634 fragment Substances 0.000 claims 12
• 238000000034 method Methods 0.000 claims 11
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
• 108091023037 Aptamer Proteins 0.000 claims 6
• 208000018737 Parkinson disease Diseases 0.000 claims 5
• 201000010099 disease Diseases 0.000 claims 5
• 239000004055 small Interfering RNA Substances 0.000 claims 5
• 241000124008 Mammalia Species 0.000 claims 4
• 208000027418 Wounds and injury Diseases 0.000 claims 4
• 230000006378 damage Effects 0.000 claims 4
• 208000035475 disorder Diseases 0.000 claims 4
• 230000012010 growth Effects 0.000 claims 4
• 238000000338 in vitro Methods 0.000 claims 4
• 208000014674 injury Diseases 0.000 claims 4
• 230000008929 regeneration Effects 0.000 claims 4
• 238000011069 regeneration method Methods 0.000 claims 4
• 230000004083 survival effect Effects 0.000 claims 4
• 208000027089 Parkinsonian disease Diseases 0.000 claims 3
• 206010034010 Parkinsonism Diseases 0.000 claims 3
• 108091027967 Small hairpin RNA Proteins 0.000 claims 3
• 230000001086 cytosolic effect Effects 0.000 claims 3
• 230000001737 promoting effect Effects 0.000 claims 3
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
• 208000001089 Multiple system atrophy Diseases 0.000 claims 2
• -1 SEQ ID NO: 2 amino acid Chemical class 0.000 claims 2
• 108020004459 Small interfering RNA Proteins 0.000 claims 2
• 210000004899 c-terminal region Anatomy 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 230000007850 degeneration Effects 0.000 claims 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
• 239000013604 expression vector Substances 0.000 claims 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
• 229920000642 polymer Polymers 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 208000024827 Alzheimer disease Diseases 0.000 claims 1
• 102000014461 Ataxins Human genes 0.000 claims 1
• 108010078286 Ataxins Proteins 0.000 claims 1
• 206010004153 Basal ganglion degeneration Diseases 0.000 claims 1
• 102000053642 Catalytic RNA Human genes 0.000 claims 1
• 108090000994 Catalytic RNA Proteins 0.000 claims 1
• 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
• 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
• 201000004315 EAST syndrome Diseases 0.000 claims 1
• 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
• 206010019196 Head injury Diseases 0.000 claims 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
• 208000023105 Huntington disease Diseases 0.000 claims 1
• 208000009829 Lewy Body Disease Diseases 0.000 claims 1
• 201000002832 Lewy body dementia Diseases 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• 208000025966 Neurological disease Diseases 0.000 claims 1
• 240000007817 Olea europaea Species 0.000 claims 1
• 208000024777 Prion disease Diseases 0.000 claims 1
• 102000007562 Serum Albumin Human genes 0.000 claims 1
• 108010071390 Serum Albumin Proteins 0.000 claims 1
• 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
• 208000018839 Wilson disease Diseases 0.000 claims 1
• 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 230000000692 anti-sense effect Effects 0.000 claims 1
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
• 206010008129 cerebral palsy Diseases 0.000 claims 1
• 230000001054 cortical effect Effects 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 206010014599 encephalitis Diseases 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 230000003993 interaction Effects 0.000 claims 1
• 210000000653 nervous system Anatomy 0.000 claims 1
• 208000002040 neurosyphilis Diseases 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 230000026731 phosphorylation Effects 0.000 claims 1
• 238000006366 phosphorylation reaction Methods 0.000 claims 1
• 229920001515 polyalkylene glycol Polymers 0.000 claims 1
• 238000002360 preparation method Methods 0.000 claims 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
• 238000000746 purification Methods 0.000 claims 1
• 230000000306 recurrent effect Effects 0.000 claims 1
• 108091092562 ribozyme Proteins 0.000 claims 1
• 201000000980 schizophrenia Diseases 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1
• 239000013603 viral vector Substances 0.000 claims 1